



HAL
open science

Antimicrobial resistance profiles of *Streptococcus suis* isolated from pigs, wild boars, and humans in France between 1994 and 2020

Manon Dechêne-Tempier, Eric Jouy, Marie-Hélène Bayon-Auboyer, Stéphanie Bougeard, Claire Chauvin, Virginie Libante, Sophie Payot, Corinne Marois-Créhan

► To cite this version:

Manon Dechêne-Tempier, Eric Jouy, Marie-Hélène Bayon-Auboyer, Stéphanie Bougeard, Claire Chauvin, et al.. Antimicrobial resistance profiles of *Streptococcus suis* isolated from pigs, wild boars, and humans in France between 1994 and 2020. *Journal of Clinical Microbiology*, 2023, 61 (9), pp.e0016423. 10.1128/jcm.00164-23 . anses-04228454

HAL Id: anses-04228454

<https://anses.hal.science/anses-04228454>

Submitted on 18 Oct 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

1 Research Articles

2

3 Antimicrobial resistance profiles of *Streptococcus suis* isolated from pigs, wild boars and humans in
4 France between 1994 and 2020

5

6 Manon Dechêne-Tempier^{a,b}, Eric Jouy^a, Marie-Hélène Bayon-Auboyer^c, Stéphanie Bougeard^d,
7 Claire Chauvin^d, Virginie Libante^b, Sophie Payot^b, Corinne Marois-Créhan^{a#}

8 ^a Anses, Mycoplasmaology, Bacteriology and Antimicrobial resistance Unit, Ploufragan-
9 Plouzané-Niort laboratory, BP53, F-22440 Ploufragan, France

10 ^b Université de Lorraine, INRAE, DynAMic, F-54000 Nancy, France

11 ^c LABOCEA, Zoopôle CS 30054, F-22440 Ploufragan, France

12 ^d Anses, Epidemiology, Health and Welfare Unit, Ploufragan-Plouzané-Niort laboratory, F-
13 22440 Ploufragan, France

14

15 Running Head: Antimicrobial resistance patterns of *S. suis* in France

16

17 # Address correspondence to Corinne Marois-Créhan, Corinne.MAROIS@anses.fr

18

19 **Abstract**

20 *Streptococcus suis*, an emerging zoonotic pathogen, causes invasive infections and substantial
21 economic losses in the pig industry worldwide. Antimicrobial resistance against 22 antibiotics
22 was studied for 200 *S. suis* strains collected in different geographical regions of France. Most
23 of the strains (86%) showed resistance to at least one antibiotic, with a low rate of resistance to
24 fluoroquinolones, penicillins, pleuromutilin and diaminopyrimidine-sulphonamides, and a
25 higher rate to macrolides-lincosamides and tetracycline. Multi-resistance patterns were
26 observed in 138 strains, three of them being resistant to six antibiotic families. Statistical
27 analyses highlighted a decrease in the resistance to trimethoprim-sulphamethoxazole, in our
28 collection, between the two periods studied — before 2010 and after 2015 — as well as an
29 impact of the geographical origin, with a higher rate of resistance to macrolides-lincosamides
30 and penicillin in Brittany than in the other French regions. Furthermore, macrolides-
31 lincosamides and tetracycline resistance patterns were more likely to be found in pig isolates
32 than in human and wild boar isolates. A difference in resistance was also observed between
33 serotypes. Most of the penicillin-resistant strains belong to serotypes 1, 5, 9, 11, 12, 15, 27 and
34 29. Finally, penicillin and pleuromutilin resistances were mostly found in “non-clinical”
35 isolates. The empirical treatment of human and porcine infections due to *S. suis* in France can
36 therefore still be carried out with beta-lactams. However, this study emphasises the need to
37 monitor antimicrobial resistance in this zoonotic pathogen.

38 **Keywords:** *Streptococcus suis*, pathogen, antimicrobial resistance, CLSI, disc diffusion
39 method.

40 **1. Introduction**

41 *Streptococcus suis* is a zoonotic pathogen causing pig infections and substantial economic
42 losses. Even though serotype 2 is preponderant, other serotypes can be responsible for
43 infections worldwide (1). In Europe, serotypes 9, 2 and 7 are dominant among clinical pig

44 isolates (61%, 18% and 7% of the isolates, respectively) whereas serotypes 1/2 and 3 are also
45 frequently found in the rest of the world (2, 3). Together with serotypes, Weinert et al. proposed
46 to group *S. suis* strains into three groups or pathotypes according to their isolation sites: [1]
47 “non-clinical”, [2] “respiratory” or [3] “systemic” (4). These groups correspond to the [1]
48 commensal, [2] possibly opportunistic, and [3] pathogenic groups defined by Estrada et al. (5).
49 These authors also suggested using the serotype to predict the pathotype, as they demonstrated
50 a link between serotypes and pathotypes (5). Human cases of *S. suis* were mainly described in
51 Asia, with three large outbreaks in China reported in 1998, 2005 and 2016 (6). Clinical
52 manifestations of *S. suis* infection include meningitis, septicaemia, endocarditis and arthritis
53 (7). In France, human infections are scarce, the eighth French case since 1995 having been
54 reported in 2016 (8) and the latest case corresponds to a woman hospitalised for meningitis after
55 preparing wild boar meat, with *S. suis* identified as the causative agent of the disease (7).

56 Several families of antimicrobials are commonly used in veterinary medicine to treat bacterial
57 infections. These include tetracyclines, beta-lactams, polymyxins, macrolides-lincosamides,
58 aminoglycosides, sulphonamides or trimethoprim-sulphonamides (TMPSs) (9). The antibiotic
59 families mostly prescribed for gastrointestinal pig infections worldwide are tetracyclines,
60 lincosamides, pleuromutilins and macrolides (10-13). Chlortetracycline, tetracycline and
61 amoxicillin are used for treating respiratory and infectious diseases (14, 15). In France,
62 tetracycline, beta-lactams (penicillins), macrolides and TMPSs are generally used for
63 respiratory infections, polypeptides and tetracycline for sepsis and gastrointestinal infections
64 (12). beta-lactams (penicillins) are indicated for treating *S. suis* meningitis, septicaemia and/or
65 arthritis (12). In France, the regulation of antibiotics in veterinary medicine must meet French
66 and European standards. The use of these molecules is subject to marketing authorisations and
67 be indicated in the "Summary of product characteristics" (SPC) sheet. Checks are made on their
68 distribution, prescription and use in accordance with European laws. In 2010, the European

69 Union initiated a common European programme called “One Health” (16). This programme is
70 based on the premise that there is a direct link between human health, animal health and more
71 generally environmental health. In 2012, France implemented its first “EcoAntibio” plan in
72 order to reduce the use of antibiotics nationwide by more than 25% in 5 years. This plan was a
73 success, as the use of antibiotics dropped by 37% (9). Resapath (a French surveillance network
74 for antimicrobial resistance in bacteria from diseased animals) is part of the antimicrobial
75 resistance surveillance system for animals set up in France. The Resapath network collects and
76 analyses data from routine antimicrobial susceptibility tests (disc diffusion method) performed
77 by diagnostic laboratories in the network, and publishes an annual report. For *S. suis*, this report
78 includes the proportions of susceptible isolates for 12 antibiotics (amoxicillin, oxacillin,
79 erythromycin, tylosin, spiramycin, lincomycin, streptomycin, kanamycin, gentamicin,
80 tetracycline, doxycycline and trimethoprim-sulphonamides) (17). Except from Resapath, few
81 data on the resistance of *S. suis* in France are available in the literature (18, 19). Therefore, the
82 aim of this study was to investigate resistance of a collection of *S. suis* strains isolated in France
83 to a larger number of antimicrobials. This collection of strains was fully characterised regarding
84 serotype, and included strains isolated from humans and wild boars. The statistical associations
85 between resistance/susceptibility and the isolation period, the strain’s geographical origin,
86 serotype, host and pathotype were analysed.

87 **2. Materials and Methods**

88 **2.1. Bacterial strains**

89 Two hundred isolates of *S. suis* were selected from the ANSES strain collection (n=1,619),
90 resulting from different research programs, in order to get a set of strains representative of the
91 diversity of serotypes, geographical origins and hosts available. All strains isolated from human
92 cases or wild boar were selected. This set included 21 strains of serotype 1, 20 of serotype 1/2,
93 32 of serotype 2, 30 of serotype 3, 30 of serotype 7, 33 of serotype 9, and 34 strains of other

94 serotypes (6 strains of serotype 4 and 1 or 2 strains of each of the following serotypes: 5, 8, 10,
95 11, 12, 14, 15, 16, 18, 21, 24, 27, 28, 29 and 31) (Table S1). In France, more than 50% of
96 national swine production is based in Brittany, so we chose to include 130 strains collected in
97 Brittany and 70 from other regions of France. Most of the strains were isolated from pigs
98 (n=178); the remaining 22 were isolated from humans (n=13) or wild boars (n=9). Strains were
99 allocated to two groups according to the isolation period (88 strains for the “before 2010” group,
100 and 112 for “after 2015”) to examine a potential impact of the French EcoAntibio plan. Finally,
101 strains were classified into three pathotypes. The “systemic” group contained 127 strains
102 isolated from samples of the nervous system, blood or joint when the causes of death were
103 attributed to an infection by this pathogen. The “respiratory” group hosted 31 strains isolated
104 from pulmonary samples obtained either from sick or clinically healthy animals on farms that
105 had had outbreaks of *S. suis* infections. The strains in the “non-clinical” group (n=36) were
106 from the upper respiratory tract with no sign of *S. suis* infection in animals and 6 strains were
107 not classified due to a lack of information. More details can be found in the supplementary data
108 (Table S1). All the strains used were confirmed by serotyping using the PCR method described
109 by Okura et al. (20).

110 **2.2. Culture conditions and antimicrobial susceptibility testing**

111 All the strains were stored at -80°C in buffered peptone water solution with glycerol (20%).
112 Each strain was sub-cultured on Columbia Agar with 5% Sheep Blood (BIO-RAD®, Marne la
113 Coquette, France) and incubated overnight at 37°C under 5% CO₂. Antimicrobial susceptibility
114 was tested using the disc (agar) diffusion method, according to Clinical Laboratory Standards
115 Institute (CLSI) standards (VET01-A and VET01-S) (21, 22). Briefly, an inoculum of 1.10⁸
116 CFU per mL was prepared for each strain and used to inoculate a Mueller-Hinton plate
117 containing 5% of sheep blood (120-mm square plates, BIO-RAD®) before the application of
118 antimicrobial discs (BIO-RAD, Marne-La-Coquette, France or Mast Diagnostics, Amiens,

119 France). The plates were incubated 22 hours \pm 1 hour at 35°C and, after bacterial growth,
120 inhibition zone diameters were measured with a sliding calliper. The reference strain *S.*
121 *pneumoniae* ATCC 49619 was used as a quality control according to CLSI recommendations.

122 As *S. suis* is a zoonotic bacterium, the antimicrobials studied belong to either the veterinary or
123 human medicine list or to both. For strains found resistant to penicillins and fluoroquinolones
124 by disc diffusion method, the minimal inhibitory concentration was determined using
125 MICRONAUT-S microplates (from MERLIN, Bruker). These microplates were used according
126 to the manufacturer's instructions.

127 **2.3. Strain categorisation**

128 Antimicrobial susceptibility test results were used to differentiate between strains without or
129 with acquired resistance mechanisms (wild-type (WT) or non-wild-type (NWT) respectively)
130 using cut-off values (COWT). The normalised resistance interpretation (NRI) method was
131 applied for each antibiotic to determine these COWT values. (23, 24). The NRI method applied
132 to the disc diffusion antimicrobial susceptibility testing was precisely described by Kronvall
133 and Smith (23) and the related Excel program is freely accessible to the following website link:
134 <http://www.bioscand.se/nri/>. The clinical interpretative criteria specified in CLSI (22) were also
135 used when available. When the COWT calculation was not possible, the strain was categorised
136 using the threshold diameters described in the literature and observations of the measured
137 diffusion diameters (25-27). In this study the WT term will be express as susceptible to the
138 antibiotic tested and NWT will be express as resistant to the antibiotic tested.

139 **2.4. Statistical analyses**

140 The strains were classified according to different resistance profiles (Table S1) in proportion to
141 their resistance/susceptibility to the antibiotics tested. In total, 24 resistance profiles were
142 identified following the analyses carried out. The first (univariate) step entailed using a Chi-
143 squared test and Fisher correction (required for limited expected counts) to explore for each

144 antibiotic possible links with other antimicrobial resistance rates together with links between
145 each antimicrobial resistance profile and the isolation period, serotype, geographical origin,
146 host and/or pathotype. The second (multivariate) step considered all the antimicrobial
147 resistances. First, a multiple correspondence analysis (MCA) was performed to illustrate
148 whether the antimicrobial resistance rates for the different antibiotics or the antimicrobial
149 resistance profiles depend on the isolation period, serotype, geographical origin, host and/or
150 pathotype (the latter variables being considered as supplementary in the analysis). Then, a
151 multiple factor analysis (MFA) was used to determine whether there is a correlation between
152 the antimicrobial resistance observed for the antibiotics of the same family and antibiotics of
153 different families. For this purpose, each family was considered as a block of variables. In order
154 to ensure robustness of the various tests and analyses, statistical analyses were performed only
155 on groups with at least five representative strains. All the analyses were performed using the R
156 software with the FactoMineR package (28). Only results with a p-value equal to or lower than
157 0.05 were considered significant and subsequently interpreted.

158 **3. Results**

159 **3.1. Determination of cut-off values using the NRI method**

160 The NRI method applied to the distributions of inhibition zone diameters can be used to define
161 two groups corresponding to the two observed populations divided by the COWT (Table 1).
162 Only one population was observed for gentamicin, chloramphenicol, florfenicol, linezolid,
163 quinupristin/dalfopristin and vancomycin. Two were observed for ampicillin, penicillin,
164 cefotaxime, ceftiofur, imipenem, clindamycin, lincomycin, erythromycin, tilmicosin, tylosin,
165 enrofloxacin, levofloxacin, norfloxacin and trimethoprim-sulphamethoxazole. Finally, a
166 complex pattern was observed for tiamulin and tetracycline. In the absence of CLSI clinical
167 interpretative criteria, the COWT value was therefore determined manually for tiamulin and the
168 CLSI's interpretive criteria for *Streptococcus* spp. were used for tetracycline.

169

170

171 Table 1: Normalised Resistance Interpretation cut-off value obtained with the disc diffusion
 172 method for 200 *S. suis* strains.

Class	Antimicrobial agent	Disc load (µg)	Distribution pattern	NRI cut-off value (mm)*	CLSI (mm)**	Wild-type population (mm)	Non-wild-type population (mm)
<i>Aminoglycosides</i>	Gentamicin	500	Unimodal	23		23-39	NA ²
<i>β-Lactams</i>	Ampicillin	2	Multi-modal	23		24-38	13-22
	Penicillin G	1	Multi-modal	19		19-32	6-17
	Cefotaxime	30	Multi-modal	24		24-38	NA ²
	Ceftiofur	30	Multi-modal	24	≥21 (S) <i>S. suis</i>	24-36	NA ²
	Imipenem	10	Multi-modal	30		32-44	NA ²
<i>Phenicols</i>	Chloramphenicol	30	Unimodal	19	≥21 (H) <i>Streptococcus spp.</i>	19-30	NA ²
	Florfenicol	30	Unimodal	21	≥22 (S) <i>S. suis</i>	21-34	NA ²
<i>Lincosamides</i>	Clindamycin	2	Multi-modal	20	≥19 (H) <i>Streptococci</i>	20-29	6-19
<i>Macrolides</i>	Lincomycin	15	Multi-modal	22		22-32	6-21
	Erythromycin	15	Multi-modal	22	≥21 (H) <i>Streptococci</i>	32-24	6-17
	Tilmicosin	15	Multi-modal	10		10-21	6
<i>Fluoroquinolones</i>	Tylosin	30	Multi-modal	18		18-27	6-16
	Enrofloxacin	5	Multi-modal	18		20-34	14
	Levofloxacin	5	Multi-modal	18		18-32	14
	Norfloxacin	10	Multi-modal	13		16-29	6-10
<i>Pleuromutilins</i>	Tiamulin	30	Multi-modal	NA ¹		14-29	6-13
<i>Oxazolidinones</i>	Linezolid	30	Unimodal	22		24-37	NA ²
<i>Streptogramins</i>	Quinupristin/Dalfopristin	15	Unimodal	15		15-27	NA ²
<i>Tetracycline</i>	Tetracycline	30	Multi-modal	NA ¹	≥23 (H) <i>Streptococcus spp.</i>	23-33	6-22
<i>Diaminopyrimidines-sulphonamides</i>	Trimethoprim-Sulphamethoxazole	25	Multi-modal	12		12-31	6-11
<i>Glycopeptides</i>	Vancomycin	30	Unimodal	18	≥17 (H) <i>Streptococcus spp.</i>	20-32	NA ²

173 *NRI cut-off calculated for 22 antibiotics. **Interpretive criteria provided by the CLSI (22) for
 174 Swine (S) or Human (H). NA¹, no diameter cut-off available. NA², no values for the non-wild-
 175 type clusters. The CLSI Breakpoint and NRI cut-off are both expressed in millimetres, as are
 176 the values obtained for the wild-type and non-wild-type clusters.

177

178 3.2. Antibiotic susceptibility of the strains


179 No resistance was observed for the following antibiotics: Gentamicin (aminoglycosides) (to
180 high concentration levels), linezolid (oxazolidinones), quinupristin/dalfopristin
181 (streptogramins) and vancomycin (glycopeptides) (Table 1). For phenicols (chloramphenicol
182 and florfenicol), the NRI COWT and the breakpoints proposed by the CLSI differed by only
183 two and one millimetre respectively, which could lead to different interpretations for 18 strains.
184 It was decided to use the cut-off calculated by the NRI method and to classify all the strains as
185 susceptible to this family of antibiotics. Indeed, no strain differed from the wild-type population
186 for these two antimicrobials.

187 The resistance rates observed are reported in Figure 1. Less than 1% of the strains tested were
188 resistant to fluoroquinolones (this single strain was resistant to enrofloxacin, levofloxacin and
189 norfloxacin). Five percent of the strains tested showed beta-lactam resistance, with ten strains
190 resistant to penicillin G. Of these, three were also resistant to ampicillin. These results were
191 confirmed by MIC determination of penicillin G: 2 µg/mL for three strains, 1 µg/mL for four
192 strains, 0.5 µg/mL for one strain and 0.25 µg/mL for two strains. For ampicillin, MIC was 1
193 µg/mL for three strains. The breakpoints used were >0.12 µg/mL for penicillin G and >0.25
194 µg/mL for ampicillin (CLSI M100) (28). No strain was resistant to cefotaxime, ceftiofur or
195 imipenem. For pleuromutilin (tiamulin) and diaminopyrimidine-sulphonamides (TMPS), the
196 proportions of resistant strains were 8% (n=16) and 16% (n=32) respectively. One of the highest
197 resistance percentages observed was for macrolides-lincosamides, with more than 71% of the
198 strains tested having resistance profiles (to erythromycin, 69% (n=137), tilmicosin, 69%
199 (n=137), tylosin 69% (n=138), to clindamycin 71% (n=142) and lincomycin 71% (n=142)).
200 Finally, 81% of the tested strains were resistant to tetracycline (n=162).

201

202

203



204

205 Figure 1: Resistance rates observed for 200 *S. suis* strains. *The percentage of strains without or*
 206 *with resistance mechanisms (in light grey or black respectively) were represented for each*
 207 *antibiotic tested. The antibiotics are classified according to the antimicrobial family to which*
 208 *they belong.*

209

210

211 In total, 86% of the strains tested were resistant to at least one antibiotic (n=171). Among these
 212 isolates, 138 can be classified as multi-resistant as they are resistant to three families of
 213 antibiotics. Thirty-five, eight and three strains were resistant to respectively four, five or six
 214 families of antibiotics. The resistance patterns are included in the supplementary data (Table
 215 S2). The most common multi-resistance patterns observed in this study are for macrolides
 216 (erythromycin, tilmicosin, tylosin) associated with lincosamides (clindamycin, lincomycin) and
 217 tetracycline (97 strains, profile P11), followed by macrolides-lincosamides, tetracycline and
 218 trimethoprim-sulphamethoxazole (20 strains, profile P15).

219 **3.3. Prevalence of antimicrobial resistance according to the isolation period, serotype,**
220 **geographical origin, host and pathotype**


221 A significant decrease in resistance to TMPS occurred between the two periods, with a
222 proportion of resistant strains dropping from 23.5% (20/85) before 2010 to 10.4% (12/115) after
223 2015 ($p < 0.035$).

224 Serotype 2 was over-represented among lincomycin-susceptible strains, with 20 strains out of
225 61, i.e. 33% ($p = 0.001$). Interestingly, penicillin resistance was associated ($p < 0.001$) with less
226 common serotypes (two strains of serotypes 11 and 12, and one strain of serotypes 1, 5, 9, 15,
227 27 and 29). A similar result was observed for tiamulin-resistant strains, there being an over-
228 representation of the serotypes classified under “others“, with seven strains out of sixteen from
229 serotypes 1 or 9 (three and four strains respectively) compared with nine strains from serotypes
230 5, 12, 15, 16, 27, 29 and 31 (1, 2, 1, 1, 1, 1 and 2 strains respectively) ($p < 0.001$). Strains with
231 these serotypes are less frequent and thus less studied than the others. Finally, among the thirty-
232 two TMPS-resistant strains, there was an over-representation ($p \leq 0.01$) of serotypes “1/2”
233 (nine strains), “others” (seven strains) and serotype 3 (six strains).

234 The resistance profiles of the strains can also be correlated with their geographical origin. An
235 over-representation of resistance to the macrolide and lincosamide families and penicillin was
236 observed in strains collected in Brittany (erythromycin $p = 0.017$, tilmicosin $p = 0.017$, tylosin
237 $p = 0.012$, clindamycin $p = 0.019$, lincomycin $p = 0.019$, and penicillin $p = 0.016$).

238 Furthermore, strains isolated from humans or wild boars appear to have fewer acquired
239 resistance mechanisms to macrolides (erythromycin $p < 0.001$, tilmicosin $p < 0.001$, tylosin p
240 < 0.001), lincosamides (clindamycin $p = 0.002$, lincomycin $p = 0.001$) and tetracycline ($p =$
241 0.003) than strains isolated from pigs. However, these results must be taken with caution since
242 in the collection the number of strains isolated from humans or wild boar ($n=22$) is much lower
243 than the number of strains isolated from pigs ($n=178$).

244 Finally, regarding the correlations between resistance profiles and pathotypes, penicillin and
 245 TMPS resistances are more frequently found in “non-clinical” or “respiratory” isolates ($p <$
 246 0.001 , $p = 0.011$ respectively) than in systemic isolates.
 247 The multiple factor analysis (MFA), confirmed by Chi-squared test, revealed an association
 248 between antimicrobial resistances to tetracycline, macrolides (tylosin, erythromycin,
 249 tilmicosin) and lincosamides (lincomycin and clindamycin) ($p < 0.001$) and between resistances
 250 to penicillin and tiamulin ($p < 0.001$) (Figure 2 (A)). An association between TMPS resistance
 251 and lincosamides (lincomycin and clindamycin) resistance was also observed but to a lesser
 252 extent ($p = 0.042$).
 253



254
 255 Figure 2: Comparative analysis of the resistance profiles of 200 strains of *S. suis* isolated in
 256 France against antibiotics belonging to different families. (A) *Multiple factor analysis of*
 257 *antibiotic resistances: the different antibiotics belonging to the same family are represented*
 258 *using the same colour code. Yellow was attributed to tetracycline, brown to lincosamides, red*
 259 *to macrolides and blue, grey and black to penicillin, tiamulin and trimethoprim-*
 260 *sulphamethoxazole respectively. Resistances are noted '_R' and susceptibilities '_S'.*

261 *Abbreviations: TET: tetracycline, L: lincomycin, CD: clindamycin, E: erythromycin, TIL:*
262 *tilmicosin, TYL: tylosin, PG: penicillin G, TIA: tiamulin, TS: trimethoprim-sulphamethoxazole.*
263 *(B) Multiple correspondence analysis of all variables: In blue, black, yellow, red and pink:*
264 *active variables (which were used to build the MCA): isolation periods (A2010, B2010),*
265 *serotypes (1, 1/2, 2, 3, 7, 9, “Others”) geographical origins (Bzh, nBzh), hosts (swine, wild*
266 *boars and Humans) and pathotypes (systemic, respiratory and non-clinical) respectively. In*
267 *green: additional variables (resistance profiles) (the correspondence table of the resistance*
268 *profiles is available as additional data, Table S2).*

269

270 The multiple correspondence analysis (MCA) (Figure 2 (B)) and Chi-squared test revealed a
271 statistically significant link between a systemic pathotype and an antimicrobial resistance to
272 macrolides and/or lincosamides and/or tetracyclines. A significant link was also found between
273 the serotype “others”, the geographical origin “Brittany”, the pathotypes “non-clinical” or
274 “respiratory” and resistance to beta-lactams and pleuromutilin. The Chi-squared test also
275 showed the influence of serotypes and pathotypes on the resistance profiles observed in this
276 study ($p < 0.001$ and $p < 0.001$ respectively).

277

278 **4. Discussion**

279 The strains with an acquired resistance mechanism were differentiated from those without (non-
280 wild type versus wild type) by calculating the COWT values of 22 antibiotics using the NRI
281 method. When the COWT calculation was not possible, the strain was categorised using the
282 threshold diameters described in the literature (25-27) and observations of the measured
283 diffusion diameters. Five antibiotics are documented with MIC for *S. suis* in the CLSI’s
284 VET01S (22) (penicillin G, ceftiofur, enrofloxacin, florfenicol and tetracycline) but
285 interpretation diameters are given for only two of them (ceftiofur and florfenicol). The COWT

286 values obtained with the NRI method for ceftiofur and florfenicol in this work do not differ
287 more than two millimetres from the interpretation diameters indicated in the CLSI's VET01S
288 for *S. suis* (22). Likewise, the interpretation diameters indicated for *Streptococcus* spp only
289 differ by two millimetres at most from the COWT values obtained with the NRI method for
290 chloramphenicol and vancomycin.

291 No strain appeared resistant to linezolid (oxazolidinone), quinupristin-dalfopristin
292 (streptogramins A+B), vancomycin (glycopeptides) and gentamicin (to high concentration
293 level). Oxazolidinone (linezolid) appears to be very efficient against most Gram-positive
294 bacteria, including pathogens of importance for human health (29). To our knowledge, *S. suis*
295 resistance to linezolid and more broadly to the oxazolidinone family has only been reported in
296 Asia in recent years (30-34). Two genes conferring two types of resistance mechanisms are
297 known in the literature, the *cfr* gene (coding an rRNA methyltransferase) and the *optrA* gene
298 (coding an ABC transporter) (35). The absence of resistance to linezolid in our collection of
299 strains confirms that this resistance is not present or very rare in *S. suis* in France.
300 Streptogramins are used against numerous highly-resistant pathogens and are therefore
301 classified as antibiotics for last-resort human therapy (36, 37). Streptogramin A resistance in *S.*
302 *suis* conferred by the *cfr* gene and *lsa(E)* gene (coding an ABC transporter) has only been
303 described in a few genomics studies (29, 30, 34, 38, 39). These genes are combined with an
304 *erm(B)* gene in order to provide resistance to the quinupristin-dalfopristin combination tested
305 in our work. Vancomycin is among the last-resort antimicrobial agents for the treatment of
306 multidrug-resistant Gram-positive bacterial infections (40). Resistance to vancomycin has been
307 reported in China but not yet in Europe and more specifically in France, to our knowledge (32,
308 40). This can be explained by the difference in use specific to each country and the nature of
309 this resistance, as resistance is due to the presence of the VanG-type resistance operon (40). *S.*
310 *suis* has a naturally low level of resistance to aminoglycosides. This family of antibiotics is

311 currently used in combination with beta-lactams in veterinary practice and is among the
312 critically important antimicrobials (37). High-level resistance to aminoglycosides is due to
313 several genes encoding three types of target modification enzymes leading to their inactivation,
314 and are encoded by the *aac*, *aph* and *ant* genes (35). The Resapath network indicated the
315 presence in France of a low rate (<2%) of high-level resistance in *S. suis* isolated from diseased
316 pigs in 2019 (2% for streptomycin, 4% for kanamycin, 0% for gentamicin) (17). Our results are
317 therefore in accordance with Resapath findings.

318 Using the NRI cut-off, none of the *S. suis* strains appeared resistant to the two phenicols tested
319 (chloramphenicol and florfenicol). The resistance mechanisms to phenicols are mediated by the
320 *cfr* and *optrA* genes discussed above, which confer resistance to linezolid. Another resistance
321 mechanism is chloramphenicol acetyl-transferase mediated by the *cat* gene (35). In Europe,
322 phenicol resistance in *S. suis* is less common than in Asia (35). Thus, the absence of resistance
323 observed in this study is consistent with the observations reported in the literature (18, 26).

324 Only one strain resistant to fluoroquinolones was identified in our collection. The resistance
325 was confirmed by MIC determination. This serotype-5 strain, isolated in 2009, has a
326 multiresistance profile as it is also resistant to macrolides-lincosamides, tetracycline,
327 pleuromutilin, diaminopyrimidine-sulphonamide and penicillins. In Asia, the reported
328 resistance rate to enrofloxacin is higher (21-32.8% before 2010 and 28.8% after 2010) than in
329 both Europe (2% before 2010 and 1-5.3% after 2010), and North America (1.4% between 2006
330 and 2016) (25, 27, 41-43). The resistance rate measured in our work is consistent with the rate
331 measured in Europe. Fluoroquinolone usage represents 2.4% of the total use of antibiotics in
332 global pig production (12). Two types of resistance mechanisms have been described in the
333 literature: mutations in the targets of fluoroquinolones (DNA gyrase and topoisomerase IV) and
334 efflux by an ABC transporter (*sat(A)* and *sat(B)* genes) (35).

335 Among the 200 strains tested, 5% were resistant to at least one antibiotic of the beta-lactam
336 family. In France, the Resapath network registered a resistance rate to beta-lactams lower than
337 5% in 2019 (17). In Asia, the resistance rate to ampicillin (0.6-23% before 2010) is higher than
338 both North America (2.3-3% before 2010 and 0.6% after 2010), and South America (0.5%) (25,
339 27, 44). Resistance to ampicillin was reported to be lower than resistance to penicillin or
340 ceftiofur (35). This is the case in our study for penicillin, with three strains resistant to ampicillin
341 and ten strains resistant to penicillin G. A decrease in penicillin G resistance has been observed
342 in North America (14-14.5% before 2010 dropping to 6.9% after 2010) whereas the resistance
343 rate remains stable in Asia and Europe (respectively 0.9-27% and 13.5% in Asia and 0-13%
344 and 2.6-5% in Europe before and after 2010) (25, 43). In this study, no difference between the
345 two time periods were observed, in accordance with the literature. Overall, the resistance rate
346 measured in this study is similar to the rate reported in Europe (Denmark, England and Sweden)
347 but lower than the rate measured in North America and Asia (25-27, 41, 43). Penicillins — and
348 especially amoxicillin — is the molecule used for first-line treatment of *S. suis* infections. Thus,
349 investigations were pursued on the ten *S. suis* strains resistant to beta-lactams. Determination
350 of the MIC indicated that ten strains were resistant to penicillin. All the strains resistant to
351 penicillin were isolated from pigs in Brittany, and were categorised as “non-clinical” for five
352 strains, “respiratory” for one strain and “systemic” for one strain, while the pathotype of three
353 other strains was unknown. The resistant strains belong to various serotypes and were isolated
354 at different periods of time: serotypes 1 (1 strain), 5 (1 strain), 9 (1 strain), 11 (2 strains), 12 (2
355 strains), 27 (2 strains), and 29 (1 strain). In this study, none of the strains tested was resistant to
356 cephalosporins. This is in accordance with the much lower level of resistance to cephalosporin
357 described in Europe (0.7% before 2010 and 0% after 2010) than in Asia and North America
358 (0.6-23% before 2010 and 0.9% after 2010 for Asia and 1-23.1% before 2010 and 9.3% after

359 2010 for North America) (25). Resistance to beta-lactams is due to modifications within the
360 signal peptide region of certain penicillin-binding-proteins (*mraY* gene) (39).

361 Some of the strains tested showed acquired resistance mechanisms against pleuromutilins (8%
362 of the strains are resistant to tiamulin). No data is available from Resapath for comparison.
363 Resistance of *S. suis* to pleuromutilins has been observed worldwide (1.9% in Brazil and >10%
364 in North America and Denmark) (27, 41, 44). In our study, the serotype seems to influence the
365 pleuromutilins resistance profiles observed, with three strains of serotype 1, four of serotype 9,
366 and 9 of serotype “others” (one strain of serotype 5, two of serotype 12, one each of serotypes
367 15, 16, 27 and 29, and two of serotype 31). Tiamulin is the third most-used drug in pig
368 production (12, 41), being prescribed for swine dysentery, colitis or ileitis and pneumonia (45).
369 Resistance mechanisms are encoded by two genes, the *cfp* gene and ABC-transporter *Isa(E)*
370 (33). Trimethoprim-sulphamethoxazole resistance was encountered in 16% of the studied
371 strains (13% registered by the Resapath network) (17). Before 2010, North America had a low
372 resistance rate (1-1.2%), while in Asia and Europe resistance rates were variable (0-59.1% and
373 0-51.5% respectively) (25). After 2010, the resistance rate in North America (2%) was still low
374 (27). In Europe, the resistance rate appears to be around 10% (8.6% in Denmark and 12% in
375 England), i.e. in the same range as observed in our strain collection (26, 41). Trimethoprim-
376 sulphamethoxazole is an old antibiotic combination used in pig production (12). In our study,
377 the resistance rate to these antibiotics differs according to the isolation period, with a significant
378 reduction in resistance between the two time periods. One third of the resistant strains were of
379 serotype 1/2. Finally, among the 30 strains classified as “respiratory”, 11 were TMPS-resistant.

380 A high proportion of strains resistant to macrolides-lincosamides was observed (71%). In
381 France, the Resapath annual report indicated in 2019 a figure of 60% for resistance to
382 macrolides and lincosamides (54% for erythromycin, 65% for tylosin, 58% for spiramycin and
383 61% for lincomycin) (17). The resistance rate measured in this study is thus above that reported

384 by Resapath but in the range described in Europe (up to 75% for erythromycin and 8% to 87.4%
385 for clindamycin) (25). The erythromycin resistance rate increased in Asia after 2010 (96.8% in
386 China) (43) but appears to have decreased in some European countries (48% in Denmark and
387 46% in England) (26, 41). Variations in the rate of resistance to macrolides-lincosamides are
388 observed worldwide, possibly explained by the usage of macrolides in pig production (12). In
389 our study, differences in resistance were observed according to the geographical origin of the
390 strains and the host, with a significant concentration of resistance in porcine isolates from
391 Brittany.

392 A high proportion of resistance was also observed for tetracycline (81%) in accordance with
393 the data from the Resapath network (17), which reported a resistance rate of 79% to tetracycline
394 for *S. suis* isolated from pigs in 2019. In North America and Asia, resistance rates measured for
395 tetracycline (87-100%, 86.9-96% respectively) were higher for strains isolated before 2010. In
396 Europe, the resistance rate before 2010 was relatively heterogeneous, ranging from 48% in the
397 Netherlands to 95.4% in Spain (25). After 2010, tetracycline resistance rates in Asia (97.8% in
398 China) and Europe (75% in Denmark and 91% in England) were still high (26, 41, 43). In North
399 America, resistance to oxytetracycline was also high (95.4%) (27). These observations are
400 explained by the worldwide use of tetracyclines in all pig production stages (1st class of
401 antibiotics used) (12). In our study, no change was observed in the rate of tetracycline resistance
402 between the two time periods studied. As for macrolides-lincosamides, resistance to
403 tetracyclines was higher in pigs than in humans or wild boars. The mechanisms of tetracycline
404 resistance have been well studied. They include efflux pumps and ribosome protection proteins
405 (35). The existence of numerous resistance genes may explain the diversity of the inhibition
406 diameters observed.

407 In our study, 138 strains were classified as multi-resistant. Among them, the most common
408 resistance pattern observed was the macrolides-lincosamides-tetracycline pattern (97 strains).

409 This agrees with the association between resistance to tetracycline and macrolides-lincosamides
410 detected by MFA. This resistance pattern is the most frequently described in the literature and
411 generally results from a co-localisation of a tetracycline resistance gene with an *erm(B)* gene
412 on mobile genetic elements (25-27, 35, 41, 42, 44, 47). Macrolides and tetracyclines are among
413 the most frequently used antibiotics in pig production worldwide (12). The World Health
414 Organization has also defined them, among others, as critically (macrolides) or highly
415 (lincosamides and tetracyclines) important antimicrobials for human medicine (36). In our
416 study, antibiotics used exclusively in veterinary or human medicine as well as antibiotics used
417 in both spheres were tested against strains isolated from swine, wild boars, and humans. There
418 do not appear to be differences in the resistance profiles of these strains in terms of the type of
419 medical field in which these antibiotics are used. The strain collection used for our study
420 includes a small number of human (n = 13) and wild boar (n = 9) isolates and it would be
421 beneficial to test more strains in order to confirm these results. However, this shows the
422 presence of these resistance genes as well as their persistence given the lack of selection
423 pressure for some molecules. Among all the strains tested (200), three showed resistance to six
424 antimicrobial families: beta-lactams, macrolides, lincosamides, pleuromutilins, tetracyclines
425 and trimethoprim-sulphamethoxazole. These strains belong to the least represented serotypes
426 (5, 27 and 29) in our collection and were of non-determined pathotype “not determined”, “non-
427 clinical” and “respiratory” isolates respectively.

428 In order to observe a potential impact of the French EcoAntibio plan intended to reduce the
429 prescription, sale and consumption of antibiotics, we analysed strains isolated before 2010 and
430 strains isolated after 2015. A significant change ($p = 0.035$) in the TMPS resistance rate was
431 observed (63% of resistant strains before 2010 and 38% after 2010) in our collection. Between
432 2011 and 2019, the exposure of pigs to this antimicrobial fell by 60.6% in France (17), which
433 could have a positive impact on the reduction of TMPS resistance in *S. suis*. In France, more

434 than half of national pig production is concentrated in Brittany. Overall, strains from this region
435 appear significantly more resistant than those from other French regions. In the literature, the
436 impact of the close proximity of pigs on the spread of resistance has already been studied at the
437 scale of a few herds (48) or in a country, and the link between the intensity of animal production
438 and the spread of resistance has been proven (27, 39, 41).

439 Some resistances were associated with particular serotypes. This is the case for penicillin
440 resistance found in infrequent serotypes. Further studies are needed to explain these
441 associations. It has been suggested that the serotype could predict the pathotype of *S. suis* strains
442 (5). The significant link observed in our study between “non-clinical” or “respiratory” and
443 serotypes other than serotypes 1, 2, 7 and 9 (serotypes called “other”) supports this hypothesis.
444 In addition, Hadjirin et al. pointed out a higher MIC in non-clinical isolates (39). In our study,
445 a statistically significant link was observed between the pathotypes “non-clinical” or
446 “respiratory” and resistance to penicillin and pleuromutilins. This agrees with a previous report
447 on resistance to beta-lactams mainly found in commensal strains (1). It would therefore be
448 beneficial to study these strains, which could serve as a reservoir of resistance genes. Weinert
449 et al. suggested that the respiratory tract is more ecologically diverse than systemic locations
450 (4). This environment could facilitate the appearance of resistance mutations and horizontal
451 gene transfer of mobile genetic elements. Since most resistance genes are carried by mobile
452 genetic elements in *S. suis* (49), this would lead to an enrichment of “non-clinical” strains in
453 resistance genes. To effectively combat antibiotic resistance, it appears vital to improve
454 understanding of antimicrobial resistance in all serotypes, but especially those not frequently
455 studied, but which can act as a reservoir of resistance genes for other bacteria.

456

457 **Supplementary Materials**

458 All the data obtain with the Anses strains and use in this paper are presented in Tables S1 and
459 S2.

460 Table S1: Antibiotic susceptibility of *S. suis* strains (n = 200) collected in France

461 Table S2: Antibiotic susceptibility/resistance profiles of *S. suis* strains (n = 200) collected in
462 France

463 **Author Contributions**

464 MDT, EJ, CM, VL, SP: funding acquisition, study design, conceptualization. MDT, CM, VL,
465 SP, MHBA: strains selections and supply. MDT, EJ, CM, VL, SP, SB: investigation, data
466 curation. SB, CC, MDT: Statistical analyses. MDT formal analysis, writing the original draft.
467 CM, VL, SP, EJ, SB, CC, MHBA: validation. MDT, CM, VL, SP, EJ, SB, CC, MHBA
468 writing—reviewing and editing. All authors have read and agreed to the published version of
469 the manuscript.

470 **Funding**

471 This research received no external funding, MDT was supported by ANSES and INRAE.

472 **Acknowledgments**

473 The automatic and manual excel programs used for the cut-off values were made available
474 through the courtesy of P. Smith, W. Finnegan, and G. Kronvall.

475 **Conflicts of Interest**

476 The authors declare no conflict of interest.

477 **References**

478 1. Segura M. 2020. *Streptococcus suis* Research: Progress and Challenges. Pathogens 9:707.

- 479 2. Goyette-Desjardins G, Auger JP, Xu J, Segura M, Gottschalk M. 2014. *Streptococcus suis*,
480 an important pig pathogen and emerging zoonotic agent-an update on the worldwide
481 distribution based on serotyping and sequence typing. *Emerg Microbes Infect* 3:e45.
- 482 3. Lacouture S, Olivera YR, Mariela S, Gottschalk M. 2022. Distribution and characterization
483 of *Streptococcus suis* serotypes isolated from January 2015 to June 2020 from diseased pigs in
484 Québec, Canada. *Can J Vet Res* 86:78–82.
- 485 4. Weinert LA, Chaudhuri RR, Wang J, Peters SE, Corander J, Jombart T, Baig A, Howell
486 KJ, Vehkala M, Välimäki, N, Harris D, Chieu TTB, Nguyen VVC, Campbell J, Schultsz C,
487 Parkhill J, Bentley SD, Langford PR, Rycroft AN, Wren BW, Farrar J, Baker S, Hoa NT,
488 Holden MTG, Tucker AW, Maskell DJ. 2015. BRaDP1T Consortium. Genomic signatures of
489 human and animal disease in the zoonotic pathogen *Streptococcus suis*. *Nat Commun* 6:6740.
490 doi: 10.1038/ncomms7740. Erratum in: *Nat Commun*. 2015;6:7272. Erratum in: *Nat Commun*.
491 2019 Nov 22;10(1):5326.
- 492 5. Estrada AA, Gottschalk M, Rossow S, Rendahl A, Gebhart C, Marthaler DG. 2019. Serotype
493 and genotype (multilocus sequence type) of *Streptococcus suis* isolates from the United States
494 serve as predictors of pathotype. *J Clin Microbiol* 57:1–16.
- 495 6. Dong X, Chao Y, Zhou Y, Zhou R, Zhang W, Fischetti VA, Wang X, Feng Y, Li J. 2021.
496 The global emergence of a novel *Streptococcus suis* clade associated with human infections.
497 *EMBO Mol Med* 13:e13810.
- 498 7. Salaneuve K, Meunier A, Aubry K. 2020. Bilateral total deafness after preparation of wild
499 boar meat. *Eur Ann Otorhinolaryngol Head Neck Dis* 137:419–421.
- 500 8. Malézieux-Picard A, De Monte A, Degand N, Grech C, Raffaelli C, Dellamonica J, Danin,
501 P-E, Dauwalder O, Cua E, Risso K. 2016. *Streptococcus suis* Meningitis in a French Cooker:
502 Case Report and Review. *J Microbiol Infect Dis* 6:136–139.

- 503 9. Anses. 2021. Suivi des ventes de médicaments vétérinaires contenant des antibiotiques en
504 France en 2020. Rapport annuel. Anses-ANMV, France.
505 https://www.anses.fr/fr/system/files/ANMV-Ra-Antibiotiques2020_0.pdf
- 506 10. Jensen VF, Jorsal SEL, Toft N. 2017. A cross-sectional study of oral antibacterial treatment
507 patterns in relation to specific diarrhoeal pathogens in weaner pigs. *Vet Microbiol* 203:18–27.
- 508 11. Hémonic A, Chauvin C, Delzescaux D, Verliat F, Corrége I, Le Coz P, Sévin JL, Liber M,
509 Chouët S, Laval A, Dupuis J, Trébaol J, Tailleur C, Da Ros Y, Amar P, Bris V, Gambade P,
510 Morgand E, Toussaint B, Chatelier N, Gérard J, Rossel R. 2018. Reliable estimation of
511 antimicrobial use and its evolution between 2010 and 2013 in French swine farms. *Porcine*
512 *Health Manag* 4:8.
- 513 12. Lekagul A, Tangcharoensathien V, Yeung S. 2019. Patterns of antibiotic use in global pig
514 production: A systematic review. *Vet Anim Sci* 7:100058.
- 515 13. Poissonnet A, Corrége I, Chauvin C, Hémonic A. 2022. Panel INAPORC, suivi des usages
516 d'antibiotiques en élevage de porcs en France entre 2010, 2016 et 2019. *Journées Recherche*
517 *Porcine*, 54, 369–370.
- 518 14. Apley MD, Bush EJ, Morrison RB, Singer RS, Snelson H. 2012. Use Estimates of In-Feed
519 Antimicrobials in Swine Production in the United States. *Foodborne Pathog Dis* 9:272–279.
- 520 15. van Rennings L, von Münchhausen C, Otilie H, Hartmann M, Merle R, Honscha W,
521 Käsbohrer, A, Kreienbrock, L. 2015. Cross-sectional study on antibiotic usage in pigs in
522 Germany. *PLoS One* 10:e0119114.
- 523 16. One Health. <https://www.who.int/europe/initiatives/one-health>. Accessed 2 Dec 2022.
- 524 17. Anses 2021. Resapath - French surveillance network for antimicrobial resistance in bacteria
525 from diseased animals, annual report on 2019 data, Lyon et Ploufragan-Plouzané-Niort, France.

526 https://resapath.anses.fr/resapath_uploadfiles/files/Documents/Rapport%20annuel/2019_Resa
527 [path_Annual%20report_GB.pdf](https://resapath.anses.fr/resapath_uploadfiles/files/Documents/Rapport%20annuel/2019_Resa).

528 18. Hendriksen RS, Mevius DJ, Schroeter A, Teale C, Jouy E, Butaye P, Franco A, Utinane A,
529 Amado A, Moreno M, Greko C, Stärk KDC, Berghold C, Myllyniemi AL, Hoszowski A, Sunde
530 M, Aarestrup FM. 2008. Occurrence of antimicrobial resistance among bacterial pathogens and
531 indicator bacteria in pigs in different European countries from year 2002 - 2004: The ARBAO-
532 II study. *Acta Vet Scand* 50:19.

533 19. Marie J., Morvan H., Berthelot-Hérault F., Sanders P., Kempf I., Gautier-Bouchardon A.
534 V., Jouy E., Kobisch M. 2002. Antimicrobial susceptibility of *Streptococcus suis* isolated from
535 swine in France and from humans in different countries between 1996 and 2000. *J Antimicrob*
536 *Chemother* 50:201–209.

537 20. Okura M, Lachance C, Osaki M, Sekizaki T, Maruyama F, Nozawa T, Nakagawa I, Hamada
538 S, Rossignol C, Gottschalk M, Takamatsu D. 2014. Development of a two-step multiplex PCR
539 assay for typing of capsular polysaccharide synthesis gene clusters of *Streptococcus suis*. *J Clin*
540 *Microbiol* 52:1714–1719.

541 21. CLSI 2018. Performance standards for antimicrobial disk and dilution susceptibility tests
542 for bacteria from animals. 5th edition. CLSI standard VET01. Wayne, PA: Clinical and
543 Laboratory Standards Institute.

544 22. CLSI 2020. Performance standards for antimicrobial disk and dilution susceptibility tests
545 for bacteria from animals. 5th edition. CLSI supplement VET01S. Wayne, PA: Clinical and
546 Laboratory Standards Institute.

547 23. Kronvall G, Smith P. 2016. Normalized resistance interpretation, the NRI method: Review
548 of NRI disc test applications and guide to calculations. *APMIS*, 124: 1023-1030.

- 549 24. Baron S, Granier S, Larvor E, Jouy E, Cineux M, Wilhelm A, Gassilloud B, Le Bouquin S,
550 Kempf I, Chauvin C. 2017. *Aeromonas* Diversity and Antimicrobial Susceptibility in
551 Freshwater-An Attempt to Set Generic Epidemiological Cut-Off Values. *Front Microbiol*
552 8:503.
- 553 25. Varela NP, Gadbois P, Thibault C, Gottschalk M, Dick P, Wilson J. 2013. Antimicrobial
554 resistance and prudent drug use for *Streptococcus suis*. *Anim Health Res Rev* 14:68–77.
- 555 26. Hernandez-Garcia J, Wang J, Restif O, Holmes MA, Mather AE, Weinert LA, Wileman
556 TM, Thomson JR, Langford PR, Wren BW, Rycroft A, Maskell DJ, Tucker AW. 2017. Patterns
557 of antimicrobial resistance in *Streptococcus suis* isolates from pigs with or without
558 streptococcal disease in England between 2009 and 2014. *Vet Microbiol* 207:117–124.
- 559 27. Hayer SS, Rovira A, Olsen K, Johnson TJ, Vannucci F, Rendahl A, Perez A, Alvarez J.
560 2020. Prevalence and time trend analysis of antimicrobial resistance in respiratory bacterial
561 pathogens collected from diseased pigs in USA between 2006–2016. *Res Vet Sci* 128:135–144.
- 562 28. Lê S, Josse J, Rennes A, Husson F. 2008. FactoMineR: An R Package for Multivariate
563 Analysis. *Journal of Statistical Software* 25:1–18.
- 564 29. Shen J, Wang Y, Schwarz S. 2013. Presence and dissemination of the multiresistance gene
565 cfr in Gram-positive and Gram-negative bacteria. *J Antimicrob Chemother* 68:1697–1706.
- 566 30. Wang Y, Li D, Song L, Liu Y, He T, Liu H, Wu C, Schwarz S, Shen J. 2013. First report
567 of the multiresistance gene cfr in *Streptococcus suis*. *Antimicrob Agents Chemother* 57:4061–
568 4063.
- 569 31. Huang J, Chen L, Wu Z, Wang L. 2017. Retrospective analysis of genome sequences
570 revealed the wide dissemination of *optrA* in Gram-positive bacteria. *J Antimicrob Chemother*
571 72:614–616.

- 572 32. Du F, Lv X, Duan D, Wang L, Huang J. 2019. Characterization of a Linezolid- and
573 Vancomycin-Resistant *Streptococcus suis* Isolate That Harbors *optrA* and *vanG* Operons. *Front*
574 *Microbiol* 10:2026.
- 575 33. Huang J, Sun J, Wu Y, Chen L, Duan D, Lv X, Wang L. 2019. Identification and
576 pathogenicity of an XDR *Streptococcus suis* isolate that harbours the phenicol-oxazolidinone
577 resistance genes *optrA* and *cfr*, and the bacitracin resistance locus *bcrABDR*. *Int J Antimicrob*
578 *Agents* 54:43–48.
- 579 34. Yang M, Li XS, Li D, Shang Y, Yu R, Schwarz S, Huang, Z, Du XD. 2020. Two novel
580 *Isa(E)*-carrying mobile genetic elements in *Streptococcus suis*. *J Antimicrob Chemother*
581 75:2689–2691.
- 582 35. Dechêne-Tempier M, Marois-Créhan C, Libante V, Jouy E, Leblond-Bourget N, Payot S.
583 2021. Update on the mechanisms of antibiotic resistance and the mobile resistome in the
584 emerging zoonotic pathogen *Streptococcus suis*. *Microorganisms* 9:1765.
- 585 36. Mast Y, Wohlleben W. 2014. Streptogramins - Two are better than one! *Int J Med Microbiol*
586 304:44–50.
- 587 37. WHO 2017. Advisory Group on Integrated Surveillance of Antimicrobial Resistance.
588 Critically important antimicrobials for human medicine: ranking of antimicrobial agents for risk
589 management of antimicrobial resistance due to non-human use.
590 <https://apps.who.int/iris/handle/10665/255027>. Accessed 2 Dec 2022.
- 591 38. Bojarska A, Molska E, Janas K, Skoczyńska A, Stefaniuk E, Hryniewicz W, Sadowy E.
592 2016. *Streptococcus suis* in invasive human infections in Poland: clonality and determinants of
593 virulence and antimicrobial resistance. *Eur J Clin Microbiol Infect Dis* 35:917–925.

- 594 39. Hadjirin NF, Miller EL, Murray GGR, Yen PLK, Phuc HD, Wileman TM, Hernandez-
595 Garcia J, Williamson SM, Parkhill J, Maskell DJ, Zhou R, Fittipaldi N, Gottschalk M, Tucker
596 AW, (Dan)Hoa NT, Welch JJ, Weinert LA. 2021. Large-scale genomic analysis of
597 antimicrobial resistance in the zoonotic pathogen *Streptococcus suis*. BMC Biol 19:191.
- 598 40. Huang J, Chen L, Li D, Wang M, Du F, Gao Y, Wu Z, Wang L. 2018. Emergence of a
599 vanG-carrying and multidrug resistant ICE in zoonotic pathogen *Streptococcus suis*. Vet
600 Microbiol 222:109–113.
- 601 41. Holmer I, Salomonsen CM, Jorsal SE, Astrup LB, Jensen VF, Høg BB, Pedersen K. 2019.
602 Antibiotic resistance in porcine pathogenic bacteria and relation to antibiotic usage. BMC Vet
603 Res 15:449.
- 604 42. Werinder A, Aspán A, Backhans A, Sjölund M, Guss B, Jacobson M. 2020. *Streptococcus*
605 *suis* in Swedish grower pigs: Occurrence, serotypes, and antimicrobial susceptibility. Acta Vet
606 Scand 62:36.
- 607 43. Zhang C, Zhang P, Wang Y, Fu L, Liu L, Xu D, Hou Y, Li Y, Fu M, Wang X, Wang S,
608 Ding S, Shen Z. 2020. Capsular serotypes, antimicrobial susceptibility, and the presence of
609 transferable oxazolidinone resistance genes in *Streptococcus suis* isolated from healthy pigs in
610 China. Vet Microbiol 247:108750.
- 611 44. Matajira CEC, Moreno LZ, Poor AP, Gomes VTM, Dalmutt AC, Parra BM, De Oliveira
612 CH, Barbosa MRF, Sato MIZ, Calderaro FF, Moreno AM. 2019. *Streptococcus suis* in Brazil:
613 Genotypic, virulence, and resistance profiling of strains isolated from pigs between 2001 and
614 2016. Pathogens 9:31.
- 615 45. Van Duijkeren E, Greko C, Pringle M, Baptiste KE, Catry B, Jukes H, Moreno MA, Pomba
616 M ; Ferreira CMPyörälä S,Rantala M,Ružauskas M, Sanders P, Teale C, Threlfall EJ, Torren-
617 Edo J,Törneke K. 2014. Pleuromutilins: use in food-producing animals in the European Union,

618 development of resistance and impact on human and animal health. J Antimicrob Chemother
619 69:2022–2031.

620 46. Zhang C, Zhang Z, Song L, Fan X, Wen F, Xu S, Ning Y. 2015. Antimicrobial Resistance
621 Profile and Genotypic Characteristics of *Streptococcus suis* Capsular Type 2 Isolated from
622 Clinical Carrier Sows and Diseased Pigs in China. Biomed Res Int 2015:284303.
623 <https://doi.org/10.1155/2015/284303>.

624 47. van Hout J, Heuvelink A, Gonggrijp M. 2016. Monitoring of antimicrobial susceptibility of
625 *Streptococcus suis* in the Netherlands, 2013–2015. Vet Microbiol 194:5–10.

626 48. Niemann L, Müller P, Brauns J, Nathaus R, Schäkel F, Kipschull K, Höltig D, Wendt M,
627 Schwarz S, Kadlec K. 2018. Antimicrobial susceptibility and genetic relatedness of respiratory
628 tract pathogens in weaner pigs over a 12-month period. Vet Microbiol 219:165–170.

629 49. Libante V, Nombre Y, Coluzzi C, Staub J, Guédon G, Gottschalk M, Teatero S, Fittipaldi
630 N, Leblond-Bourget N, Payot S. 2019. Chromosomal Conjugative and Mobilizable Elements
631 in *Streptococcus suis*: Major Actors in the Spreading of Antimicrobial Resistance and
632 Bacteriocin Synthesis Genes. Pathogens 9:22.